Murr Martina, Bernchou Uffe, Bubula-Rehm Edyta, Ruschin Mark, Sadeghi Parisa, Voet Peter, Winter Jeff D, Yang Jinzhong, Younus Eyesha, Zachiu Cornel, Zhao Yao, Zhong Hualiang, Thorwarth Daniela
Section for Biomedical Physics, Department of Radiation Oncology, University of Tübingen, Germany.
Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
Phys Imaging Radiat Oncol. 2024 May 17;30:100588. doi: 10.1016/j.phro.2024.100588. eCollection 2024 Apr.
Application of different deformable dose accumulation (DDA) solutions makes institutional comparisons after online-adaptive magnetic resonance-guided radiotherapy (OA-MRgRT) challenging. The aim of this multi-institutional study was to analyze accuracy and agreement of DDA-implementations in OA-MRgRT.
One gold standard (GS) case deformed with a biomechanical-model and five clinical cases consisting of prostate (2x), cervix, liver, and lymph node cancer, treated with OA-MRgRT, were analyzed. Six centers conducted DDA using institutional implementations. Deformable image registration (DIR) and DDA results were compared using the contour metrics Dice Similarity Coefficient (DSC), surface-DSC, Hausdorff-distance (HD95%), and accumulated dose-volume histograms (DVHs) analyzed via intraclass correlation coefficient (ICC) and clinical dosimetric criteria (CDC).
For the GS, median DDA errors ranged from 0.0 to 2.8 Gy across contours and implementations. DIR of clinical cases resulted in DSC > 0.8 for up to 81.3% of contours and a variability of surface-DSC values depending on the implementation. Maximum HD95%=73.3 mm was found for duodenum in the liver case. Although DVH ICC > 0.90 was found after DDA for all but two contours, relevant absolute CDC differences were observed in clinical cases: Prostate I/II showed maximum differences in bladder V28Gy (10.2/7.6%), while for cervix, liver, and lymph node the highest differences were found for rectum D2cm (2.8 Gy), duodenum Dmax (7.1 Gy), and rectum D0.5cm (4.6 Gy).
Overall, high agreement was found between the different DIR and DDA implementations. Case- and algorithm-dependent differences were observed, leading to potentially clinically relevant results. Larger studies are needed to define future DDA-guidelines.
应用不同的可变形剂量累积(DDA)解决方案使得在线自适应磁共振引导放疗(OA-MRgRT)后的机构间比较具有挑战性。这项多机构研究的目的是分析OA-MRgRT中DDA实施的准确性和一致性。
分析了1例使用生物力学模型变形的金标准(GS)病例以及5例接受OA-MRgRT治疗的临床病例,包括前列腺癌(2例)、宫颈癌、肝癌和淋巴结癌。六个中心使用各自机构的实施方案进行DDA。使用轮廓度量指标骰子相似系数(DSC)、表面DSC、豪斯多夫距离(HD95%)以及通过组内相关系数(ICC)和临床剂量学标准(CDC)分析的累积剂量体积直方图(DVH)来比较可变形图像配准(DIR)和DDA结果。
对于GS病例,各轮廓和实施方案的DDA误差中位数范围为0.0至2.8 Gy。临床病例的DIR中,高达81.3%的轮廓的DSC > 0.8,且表面DSC值因实施方案而异。在肝癌病例中,十二指肠的最大HD95% = 73.3 mm。尽管除两个轮廓外,所有轮廓在DDA后DVH的ICC > 0.90,但在临床病例中观察到了相关的绝对CDC差异:前列腺癌I/II中膀胱V28Gy的差异最大(分别为10.2%/7.6%),而对于宫颈癌、肝癌和淋巴结癌,直肠D2cm(2.8 Gy)、十二指肠Dmax(7.1 Gy)和直肠D0.5cm(4.6 Gy)的差异最大。
总体而言,不同的DIR和DDA实施方案之间具有高度一致性。观察到了病例和算法相关的差异,导致了可能具有临床相关性的结果。需要进行更大规模的研究来制定未来的DDA指南。